| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005145728 |
| P356 | DOI | 10.2165/00002018-199308030-00001 |
| P698 | PubMed publication ID | 8095787 |
| P50 | author | Morten Andersen | Q42725676 |
| P2093 | author name string | J S Schou | |
| P2860 | cites work | Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users | Q34396057 |
| Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up | Q34487626 | ||
| Cancer occurrence in a cohort of patients treated with cimetidine | Q34532561 | ||
| What information for the patient? Large scale pilot study on experimental package inserts giving information on prescribed and over the counter drugs | Q35171656 | ||
| Implications of the reclassification of drugs from prescription-only to over-the-counter status | Q37221129 | ||
| Alcohol and H2 receptor antagonists: over the counter, under the table? | Q37587417 | ||
| Over-the-counter drugs. The issues | Q37912533 | ||
| Dyspepsia in general practice | Q37993980 | ||
| Adverse reactions and interactions with H2-receptor antagonists | Q39460908 | ||
| Dyspepsia: a dilemma for doctors? | Q39464214 | ||
| Hepatic effects of drugs used in the treatment of peptic ulcer disease | Q39464423 | ||
| Haematological adverse effects of histamine H2-receptor antagonists | Q39471834 | ||
| Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions | Q39513613 | ||
| The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers. | Q39515445 | ||
| A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary | Q41425018 | ||
| Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy | Q42199048 | ||
| Acid suppression: how much is needed? | Q43173652 | ||
| Basis for ulcus therapy in general practice | Q43751143 | ||
| Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin | Q45014447 | ||
| Histamine-2-receptor antagonists and gastric cancer risk | Q45122478 | ||
| Adverse Reactions to H2-Receptor Antagonists in Denmark Before and After Transfer of Cimetidine and Ranitidine to Over-the-counter Status | Q50544645 | ||
| [Over-the-counter availability of potent ulcer drugs. Study of changes in the drug use pattern and the pressure on diagnostic measures] | Q64946182 | ||
| Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus | Q68287732 | ||
| Ulcer complications in the county of Funen during 1980-1990. Are there any changes in the frequency of hospitalization following the release of potent ulcer drugs for over-the-counter sale? | Q68299423 | ||
| [Adverse effects of ulcer drugs before and after release of cimetidine, ranitidine and sucralfate for over-the-counter sale] | Q68299431 | ||
| Gastric cancer--delay in diagnosis and its causes | Q68535402 | ||
| Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia | Q68859523 | ||
| Cimetidine toxicity: an assessment of 881 cases | Q69415078 | ||
| Management of dyspepsia: report of a working party | Q69914455 | ||
| Over the counter sales of histamine-2 receptor antagonists | Q69931945 | ||
| Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American College of Physicians | Q69937084 | ||
| Preparations against stomach ulcer: use, prices and subsidy before and after 27 March 1989 | Q70148711 | ||
| Long-term follow-up study of cimetidine | Q70721616 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 179-185 | |
| P577 | publication date | 1993-03-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Safety implications of the over-the-counter availability of H2-antagonists | |
| P478 | volume | 8 |
| Q42699529 | Are H2 receptor antagonists safe over the counter drugs? |
| Q34458585 | Benefits and risks of self medication |
| Q33609402 | Drug interactions and anti-infective therapies |
| Q33571851 | Formulary management of drugs for cancer-associated hypercalcaemia |
| Q42378720 | Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use. |
| Q40387167 | Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases? |
| Q40743031 | Polypharmacy. Pharmacokinetic perspectives |
| Q33560764 | Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders |
| Q77071566 | Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation |
Search more.